Methanol fraction of Calliandra portoricensis root bark activates caspases via alteration in mitochondrial viability in vivo by Oyebode, Olubukola T. et al.
Journal of Herbmed Pharmacology
J Herbmed Pharmacol. 2018; 7(4): 251-258.
Methanol fraction of Calliandra portoricensis root bark 
activates caspases via alteration in mitochondrial viability in 
vivo
Olubukola T. Oyebode1* ID , Jude O. Akinyelu2, Emmanuel A. Oamen1, Olufunso O. Olorunsogo1
1Laboratories for Biomembrane and Biotechnology Unit, Department of Biochemistry, College of Medicine, University of Ibadan, Ibadan, Oyo State, 
Nigeria
2Department of Biochemistry, School of Life Sciences, University of Kwazulu Natal, KwaZulu-Natal, South Africa
*Corresponding author: Olubukola T. Oyebode, PhD; Tel: +234 703 
134 9454, Fax: +234 281 030 43, Email: bukioyebode@gmail.com
Implication for health policy/practice/research/medical education:
High doses and prolonged use of the C. portoricensis decoction in treatment of diseases is discouraged given the potential harm 
it poses on the organs of the body. Isolation of the cell death–inducing phytochemical in the plant will be useful in the treatment 
of diseases characterized by low apoptosis.
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Introduction: Dysregulated apoptosis is associated with a number of disease conditions. 
Traditionally, Calliandra portoricensis is used in the management of prostate enlargement. This 
study investigates the in vivo effect of potent methanol fraction of C. portoricensis (MFCP) on 
mitochondrial permeability transition (mPT) pore, an important pharmacological target in 
treatment of various diseases, and examines the toxicities associated with its oral administration.  
Methods: Forty-two male Wistar strain rats (70-80 g) were divided into 6 groups of 7 animals 
each. Each group was orally administered 25, 50, 100, 200, 400 mg/kg MFCP and the control 
group received distilled water for 21 and 30 days, respectively. mPT, assay for serum enzymes and 
hematological parameters were assessed spectrophotometrically while activation of caspases 3 and 
9 was done by ELISA technique. Histological assessment of vital organs (liver, kidney, prostate) was 
carried out according to standard procedures.
Results: There were no significant effects on mPT pore at all doses administered after 21 days of 
oral administration. However, after 30 days of administration, MFCP induced mPT pore opening 
at doses 100 and 200 mg/kg with induction folds of 2.6 and 3.3, respectively while there was no 
induction of mPT pore opening at lower doses of 25 mg/kg and 50 mg/kg. Furthermore, significant 
(P < 0.05) increases in serum enzymes (ALT, AST) were observed at all doses administered when 
compared with control after 30 days of oral administration. Cell counts (Hb, PCV, RBC, WBC) 
were adversely affected at the highest dose (200 mg/kg) compared with control and other treated 
groups (25, 50 and 100 mg/kg) after 30 days of administration. Similarly, activation of caspases 
9 and 3 were observed in rat liver homogenate at high doses of the fraction while histological 
evaluation showed degeneration and distortion of organs at the highest dose.  
Conclusion: MFCP contains phytochemicals that elicit the opening of the pore and induction of 
mitochondrial-mediated apoptosis. This would be relevant in treatment of degenerative diseases 
that results from down-regulation of apoptosis. However, caution should be exercised in using high 
doses of the plant. 
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Introduction
A cell’s decision to give up its entire life following insults 
arising from within the cell or its immediate environment 
proceeds via a physiological process called apoptosis 
(programmed cell death) (1). Apoptosis is involved in 
development, removal of infected, damaged and worn-
out/aged cells that have outlived their functions, thus 
playing a major role in maintaining the body’s cellular 
homeostasis (2). Programmed cell death may involve the 
ligation of cell death receptors with their cognate ligands 
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following induction of a death signal from outside (3,4). 
This is referred to as extrinsic pathway. On the other hand, 
apoptosis may proceed via the intrinsic (mitochondrial–
mediated) pathway which requires alteration in the 
permeability of the inner mitochondrial membrane which 
results in swelling of the matrix leading to the release of 
apoptogenic proteins such as cytochrome C via the opening 
of the mitochondrial permeability transition (mPT) 
pore (5). The release of cytochrome C into the cytosol 
facilitates its binding to apoptotic protease activating 
factor-1 (APAF-1) which assembles the apoptosome 
and becomes a platform upon which pro-caspase -9, the 
mitochondrial initiator caspase, is recruited and activated. 
Activated caspase-9 activates executioner caspase-3 via 
a caspase-cascade mechanism (6). Cysteine-dependent 
aspartate specific proteases (CASPASES) are responsible 
for the morphological features exhibited by a dying cell 
such as membrane blebbing and cell shrinkage (7). Hence, 
the release of cytochrome C via the opening of the mPT 
pore is crucial for caspase activation and subsequently cell 
death. 
Given that mitochondria contribute to and accelerate 
the apoptotic process, molecular checkpoints are being 
targeted to regulate this important physiological process 
(8). In this regard, the mPT pore has become a strategic 
target in diseases involving dysregulated apoptosis. 
Certain bioactive agents present in medicinal plants elicit 
their chemo-protective effects through the induction 
or inhibition of the opening of mPT pore e.g. honokiol, 
magnolol (9,10).
 Calliandra is a genus of flowering plants in the subfamily 
Mimosaceae under the family Leguminoseae (Pea family). 
Calliandra portoricensis is a distinctive ornamental shrub 
and medicinal plant. Its local names in Nigeria are ‘Tude’ 
in Yoruba, ‘Ule’ in Igbo and ‘Oga’ in Hausa. The plant 
has also been reported to have anticonvulsant (11,12) 
antidiarrheal, antispasmodic, antipyretic, antirheumatic 
and analgesic (13) activities in humans. Besides, Moharram 
et al (14) reported that C. portoricensis has antioxidant 
and anti-bacterial properties. The plant has been shown to 
have protective effects (antidote) in Wistar rats challenged 
with snake venom (15). In folklore medicine, it is used in 
combination with Plumbago zeylanica in the traditional 
treatment of prostate tumor. Results of phytochemical 
screening revealed that methanol fraction of the root 
bark of C. portoricensis contains cardiac glycosides, 
anthraquinones, flavonoids, phenols, saponins, steroids 
and tannins. Our preliminary data reveals that methanol 
fraction of C. portoricensis (MFCP) is potent with respect 
to induction of opening of the mPT pore, enhancement 
of mitochondrial ATPase activity and activation of 
cytochrome C in vitro (16). Owing to the relevance of 
bioavailability of the compound of interest at the target site 
and to determine the safety dose regimen for the potent 
methanol fraction, in vivo assessment of the efficacy of 
the potent MFCP in induction of mPT pore opening, 
activation of caspases and the determination of its toxic 
effects in normal rat were investigated.
Materials and Methods
Dosing of experimental animals
Doses of 25, 50, 100, 200 and 400 mg/kg were selected 
based on a preliminary study. Dosing was once daily 
over the experimental period and the oral route of 




(HEPES), sucrose, rotenone, spermine, Bovine Serum 
Albumin (BSA), mannitol and all other reagents were 
purchased from Sigma-Aldrich chemical Co. (St. Louis, 
MO, USA) and were of the highest purity grade. Caspases 
9 and 3 ELISA kits were obtained from Elabscience 
Biotechnology, Ltd China. 
Collection and extraction of plant material
Freshly harvested roots of C. portoricensis were obtained 
from Oje market, Ibadan, Oyo State, Nigeria. Samples 
were identified and authenticated at the Department of 
Botany, University of Ibadan and a specimen Voucher 
no. UIH-22466 was deposited in the Herbarium. The 
roots were washed, the bark peeled and air-dried for three 
weeks in the laboratory after which they were powdered 
and weighed, air-dried, powdered root bark of C. 
portoricensis (2 kg) was soaked with sufficient methanol 
in all- glass jars at room temperature for 72 hours. The 
filtrate was concentrated under reduced pressure using a 
rotary evaporator.
Partitioning of crude methanol extract of Calliandra 
portoricensis (MECP) using vacuum liquid chromatography
Four grams silica gel 60 (0.040–0.063 mm, Merck) were 
adsorbed to 4 g MECP. The mixture was air-dried to 
obtain a powdery form. A sintered funnel for vacuum 
liquid chromatography (VLC) was packed with 8 g Silica 
gel (Hopkins and Williams, England). Solvents were added 
in order to increase polarity and n-hexane chloroform, 
ethyl acetate and methanol fractions were obtained in this 
order. The eluted fractions were concentrated using rotary 
evaporator under reduced pressure and the resulting 
concentrated solvent–free fractions were stored in glass 
sample bottles and stored at 4°C.
Isolation of rat liver mitochondria
Rat liver mitochondria were isolated essentially according 
to modified method by Johnson Lardy  (17). The nuclear 
fraction and cellular debris were pelleted by centrifuging 
the homogenate twice at 2300 rpm for 5 minutes. The 
supernatant obtained was spun at 13 000 rpm for 10 
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minutes to obtain the mitochondrial pellet which was 
washed twice with washing buffer by spinning at 12 000 
rpm for 10 minutes. The mitochondria obtained were 
immediately resuspended in appropriate volume of MSH 
buffer, and dispensed into Eppendorf tubes and kept at 
4oC and used fresh. 
Mitochondrial protein estimation
Mitochondrial protein was determined according to the 
method of Lowry et al (18) using BSA as standard.
Mitochondrial swelling assay
Mitochondrial permeability transition was determined 
according to the method of Lapidus and Sokolove 
(19). This was monitored by measuring the changes in 
absorbance of mitochondria at 540 nm in the presence and 
absence of calcium ion (triggering agent) in a Spectrumlab 
752s uv/visible spectrophotometer. Mitochondria (0.4 mg 
protein/mL) were pre-incubated in the presence of 0.8 µM 
rotenone in a medium containing 210 mM mannitol, 70 
mM sucrose, 5 mM HEPES-KOH (pH 7.4) for 3 minutes 
prior to addition of 300 µM CaCl2, while 5 mM succinate 
was added 30 seconds later and mPT was measured at 540 
nm for 12 minutes at 30 seconds interval. The inhibitory 
effect of spermine on the induction of pore opening was 
carried out prior to addition of CaCl2. The inductive 
effects of fractions were monitored when the fractions 
were replaced with CaCl2
 
Study design
Forty-two male Wistar rats (70-80 g) were divided 
into 6 groups of 7 animals each. Each group was orally 
administered 25, 50, 100, 200, 400 mg/kg of the methanol 
fraction and the control group received distilled water for 
21 and 30 days, respectively. For oral administration of 
MFCP for 30 days, the highest dosage group was 200 mg/
kg. This may be due to toxicity of the extract because no 
animal survived the 400 mg/kg dose.
Sample preparation for caspase-9 and 3 activities
Livers were excised from male Wistar rats that were 
orally administered 25, 50, 100, 200 mg/kg of the potent 
methanol fraction along with their control subjects. Each 
liver was weighed and rinsed with phosphate buffered 
saline thoroughly until a clear wash was obtained. The 
washed livers were then put in the sample bottles and 
frozen for 48 hours. After, they were brought out to 
thaw, the samples were then homogenized on ice and the 
homogenates were centrifuged at 8000 rpm for 5 minutes. 
The supernatant obtained were then used for initiator 
caspases-9 and executioner caspase-3 analyses.
Determination of caspase -3 and 9 activities
Levels of caspase-9 and 3 were determined using an 
ELISA (Elabscience Biotechnology, Ltd China) kit with 
pre-coated antibodies for CASP9 and CASP3, respectively. 
A microplate reader (DNM-9602A from china) was used 
to read optical density at 450 nm. 
Tissue preparation for histopathology
Liver, prostate and kidney were processed for 
histopathology. They were quickly removed, trimmed and 
placed in 10% formalin for about 5 days for proper fixation 
and dehydrated by ascending grades of isopropyl alcohol 
for an hour. The dehydrated organs were cleared in xylene 
and transferred into 2 changes of liquid paraffin wax. 
The tissue sections were stained in Ehrlich’s hematoxylin 
for eight minutes, washed in tap water and dipped in 
acid alcohol to remove excess stain. These were counter 
stained in 10% aqueous eosin, incubated and mounted for 
photomicrography.
Assay of serum enzymes/determination of hematological 
parameters
Alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) were measured by monitoring the 
concentration of pyruvate hydrazone formed according 
to the method described by Reitman and Frankel (20). 
Hemoglobin, packed cell volume red blood cell count and 
white blood cell counts were determined by the method 
described by Jain (21). 
Results
Effects of various doses of methanol fraction (MFCP) on 
rat liver mPT pore in the absence and presence of calcium 
(21 & 30 days) 
Mitochondria were isolated from control animals and 
mitochondrial swelling assay was carried out. There was 
no significant change in the volume of mitochondria 
respiring on succinate in the presence of rotenone in the 
mitochondria of untreated animals for 21 and 30 days 
(Figure 1).
Figure 1. Representative profiles of changes in absorbance (540 
nm) of cyclosporine A reversed calcium-ion induced mitochondrial 
membrane permeability transition pore opening (Untreated Animals 
– 21 & 30 days). 
NTA- Non triggering agent. TA, triggering agent. INH, Inhibitor 
(Cyclosporine A). 
*Typical data of one experiment are shown and similar results were 
obtained in at least 3 different preparations.
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Figures 2 and 3 show the profiles of changes in absorbance 
of mitochondria at various doses of MFCP following 
oral administration for 21 and 30 days in the absence 
of calcium. These results show that after 21 days of oral 
administration of MFCP, there were no significant effect 
on mPT pore in the absence of calcium at all doses 
administered. However, after 30 days of administration, 
MFCP induced mPT pore opening in the absence of 
calcium at 100 and 200 mg/kg with induction folds of 2.6 
and 3.3, respectively. However, there was no induction of 
mPT pore opening at lower doses of 25 mg/kg and 50 mg/
kg, while the animals could not survive the highest dose of 
400 mg/kg for 30 days.
Figures 4 and 5 show the profile of changes in absorbance 
of mitochondria at various doses of MFCP following oral 
administration for 21 and 30 days respectively, in the 
Figure 2. Representative profiles of changes in absorbance of 
mitochondria at various doses (25, 50, 100, 200 and 400 mg/kg) 
of MFCP over a period of 12 minutes in the absence of calcium 
(21 days). NTA, non triggering agent; TA, triggering agent; INH, 
Inhibitor (cyclosporine A).
*Typical data of one experiment are shown and similar results 
were obtained in at least 3 different preparations.
Figure 4. Representative profile of changes in absorbance of 
mitochondria at various doses (25, 50, 100, 200 and 400 mg/
kgbw) of MFCP over a period of 12 minutes in the presence of 
calcium (21 days). NTA, non triggering agent; TA, triggering agent 
(3mM CaCl2); INH, Inhibitor (cyclosporine A).
*Typical data of one experiment are shown and similar results 
were obtained in at least 3 different preparations.
Figure 5. Representative profile of changes in absorbance of 
mitochondria at various doses (25, 50, 100 and 200 mg/kgbw) 
of MFCP over a period of 12 minutes in the presence of calcium 
(30 days). NTA, non triggering agent; TA, triggering agent (3mM 
CaCl2); INH, Inhibitor (cyclosporine A).
*Typical data of one experiment are shown and similar results 
were obtained in at least 3 different preparations.
Figure 3. Representative profiles of changes in absorbance of 
mitochondria at various doses (25, 50, 100 and 200 mg/kgbw) 
of MFCP over a period of 12 minutes in the absence of calcium 
(30 days). NTA, non triggering agent; TA, triggering agent (3mM 
CaCl2); INH, Inhibitor (cyclosporine A).
*Typical data of one experiment are shown and similar results 
were obtained in at least 3 different preparations.
presence of calcium. The results revealed that calcium 
potentiated mPT pore opening of rat liver at doses of 200 
and 400 mg/kg after 21 days of oral administration. In this 
regard, the induction folds of 10.6 and 10.9 were obtained 
at doses 200 mg/kg and 400 mg/kg, respectively while 
calcium gave a 10.5 fold increase. Oral administration 
of lower doses of 25, 50 and 100 mg/kg had an inductive 
effect of 10.1, 10.2, 10.4 folds, respectively. Overall, the 
inductive effect was concentration-dependent. According 
to the figure, after 30 days of administration, the effect on 
mPT induction was greatly potentiated by MFCP in the 
presence of calcium at 100 and 200 mg/kg with induction 
folds of 17.6 and 19.0, respectively. Induction of mPT pore 
opening was also observed at doses 25 and 50 mg/kg with 
inductive folds of 16.8 and 17.0 while calcium gave a 17.1- 
fold increase.
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Effects of MFCP on hematological and liver enzymatic 
profiles in rats after 21 and 30 days of administration
After 21 days of administration, the packed cell volume 
of the animals increased maximally at 50 mg/kg when 
compared with control. Similar effects were also observed 
for white blood cell (WBC) and red blood cell (RBC) 
count as well as hemoglobin levels. Decreases in the levels 
of WBC, RBC, PCV and Hb were observed at doses higher 
than 50 mg/kg (Figure 6).
Figure 7 shows the in vivo effect of oral administration 
of MFCP (30 days) on hematological parameters. 
Interestingly, there were significant declines (P < 0.05) in 
the hematological parameters (PCV, WBC, RBC and Hb) 
of all the dosage groups (25, 50, 100 and 200 mg/kg) when 
compared to the control group. In this regard, cell counts 
were adversely affected at the highest dose (200 mg/kg) 
compared with control and other treated groups (25, 50 
and 100 mg/kg).
The in vivo effect of oral administration of MFCP (21 
days) on serum aminotransferases are depicted in 
Figure 8. According to the results, there were significant 
increases in the serum ALT and AST activity of 200 and 
400 mg/kg dosage groups when compared to the control 
rats after 21 days of administration. However, at all doses 
of methanol fraction administered (25, 50, 100, 200 mg/
kg), serum AST and ALT levels were significantly elevated 
when compared with the control after 30 days of oral 
administration of MFCP. The data is depicted in Figure 9.
Effects of oral administration of MFCP tissue sections 
(liver, kidney and prostate) after 30 days
Photomicrographs of liver sections are depicted in Figure 
10. As the doses of methanol fraction administered 
increased, a moderate to severe diffuse vacuolar 
degeneration of hepatocytes were observed while control 
animals had very mild diffuse vacuolation.
Figure 11 shows the photomicrographs of kidney sections 
of Wistar rats following oral administration of methanol 
Figure 6. In vivo effect of oral administration of MFCP on 
Hematological parameters (21 days). WBC, white blood cell; 
RBC, red blood cell; HB, hemoglobin; PCV, packed cell volume. 
Values are mean ± SD. P < 0.05 vs control(*).
Figure 8. In vivo effect of oral administration of MFCP on serum 
aminotransferases (21 days). WBC, white blood cell; RBC, red 
blood cell; HB, hemoglobin; PCV, packed cell volume.  Values are 
mean ± SD. P < 0.05 vs control(*).
Figure 9. In vivo effect of oral administration of MFCP on liver 
enzymatic profile (30 days). WBC, white blood cell; RBC, red 
blood cell; HB, hemoglobin; PCV, packed cell volume.  Values are 
mean ± SD. P < 0.05 vs control(*).
Figure 7. In vivo effect of oral administration of MFCP on 
Hematological parameters (30 days). WBC, white blood cell; 
RBC, red blood cell; HB, hemoglobin; PCV, packed cell volume. 
Values are mean ± SD. P < 0.05 vs control(*).
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fraction for 30 days. No visible lesions were observed in 
kidney of animals that received doses of 25, 50 and 100 
mg/kg MFCP. However, protein casts were abundant in 
kidneys of animals that received the highest dose of 200 
mg/kg.
Photomicrographs of prostate sections of animals orally 
administered methanol fraction for 30 days are shown in 
Figure 12. As seen from the figure, glandular secretions 
were observed in the prostate of animals administered 
doses 50 mg/kg and 100 mg/kg while distortion of the 
entire gland was observed at the highest dose of 200 mg/kg. 
In particular, at dose of 50 mg/kg, lumen of the glandular 
units appeared shrunken but the epithelial glands 
appeared normal while necrotic debris were observed in 
the prostate of animals that received the highest dose of 
200 mg/kg. No visible lesion was observed in the prostate 
of control animals.
Oral administration of MFCP (30 days) activates caspases 
3 and 9 activation
According to the data (Figure 13), increases in activities 
of caspases 9 and 3 were observed in liver homogenates of 
rats orally administered MFCP. In this regard, a 1.8-fold 
increase was observed at the highest dose (200 mg/kg) for 
caspase-9 while a 2-fold increase was recorded for caspase 
3 at the same dose.
Discussion
Our preliminary data reveal the in vitro inductive effect 
of the potent MFCP on mPT pore in rat liver (16). We 
investigated the apoptotic potential of MFCP in rat 
liver mitochondria with the view of establishing safety 
regimens of the fraction in vivo. mPT was assessed 
spectrophotometrically in the animal at 540 nm. 
The results obtained showed that the integrity of the 
mitochondria isolated from untreated animals were not 
compromised thus, they were suitable for further use.
After 21 days of oral administration of MFCP, the methanol 
fraction had no effect whatsoever in inducing mPT at all 
doses tested. This might be due to poor oral bioavailability 
of the active principle of the fraction which is a potential 
drawback associated with dietary compounds after 
ingestion (22). However, after 30 days of administration, 
MFCP induced mPT pore opening in the absence of 
calcium at 100 and 200 mg/kg with induction folds of 2.6 
and 3.3, respectively while there was no induction of mPT 
pore opening at doses lower than 50 mg/kg. This inductive 
effect, though at higher doses, is in consonance with the 
in vitro data. These results suggest that at higher doses of 
methanol fraction, the active compound was available at 
Figure 10. Photomicrographs of liver sections of animals orally 
administered MFCP for 30 days.(A ) control, (B) 25 mg/kg bw, (C) 50 
mg/kg bw, (D) 100 mg/kg bw, (E) 200 mg/kg bw (x400).
(A) Very mild diffuse vacuolation of hepatocytes, (B) Moderate 
vacuolar degeneration of hepatocytes, (C) Further vacuolation of 
hepatocytes, (D) Severe degeneration of hepatocytes.
Figure 11. Photomicrographs of kidney sections of animals orally 
administered MFCP for 30 days. (A ) control, (B) 25 mg/kg bw, (C) 50 
mg/kg bw, (D) 100 mg/kg bw, (E) 200 mg/kg bw (x400).
(A) No visible lesions seen, (B) slightly few lesions observed, (C) No 
visible lesions, (D) Protein casts were observed.
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the target site to interact with the components of the mPT 
pore in order to elicit inductive effect.
 Furthermore, the data revealed that oral administration 
of higher doses of MFCP for 21 (200 and 400 mg/kg) and 
30 days (100 and 200 mg/kg) potentiated calcium-induced 
opening of the pore. This suggests that methanol fraction 
elicited synergistic effect with calcium in inducing the 
opening of the mPT pore. 
Investigation of the effects of methanol fraction on 
hematological parameters after oral administration 
Figure 12. Photomicrographs of prostate sections of animals orally 
administered MFCP for 30 days.  (A ) control, (B) 25 mg/kg bw, (C) 50 
mg/kg bw, (D) 100 mg/kg bw, (E) 200 mg/kg bw (x400).
(A) No visible lesions seen, (B) Glandular secretions seen, (C)
Shrinkage of lumen of glandular units, (D) Necrotic debris/distortion 
of the entire gland.
Figure 13. Effects of oral administration of methanol fraction for 30 
days on caspase-3 and 9 activities in rat liver homogenate. P < 0.05 
vs control.
revealed that the animals tolerated the fraction up to 50 
mg/kg after which decrease in levels of all hematological 
parameters (WBC, PCV, Hb, and RBC) under investigation 
was observed, after 21 days of oral administration. 
Moreover, cell counts were adversely affected at the highest 
dose (200 mg/kg) compared with control and other 
treated groups (25, 50 and 100 mg/kg) after 30 days of 
administration. The decrease in hematological parameters 
observed may be associated with toxicity of the fraction at 
these doses. These findings suggest that MFCP could have 
hematotoxic effects which are also highly dependent on 
the dose and duration of administration.
Meyer and Harvey (23) had stated that serum enzyme 
levels could be indicative of liver function, hence, serum 
ALT and AST were determined spectrophotometrically. 
Our results showed that MFCP caused significant 
increases in the serum ALT and AST activities at 200 and 
400 mg/kg bw dosage groups after twenty-one days of 
administration. However, serum AST and ALT levels were 
significantly elevated after thirty days of administration at 
all the test groups used for this study. These results suggest 
that MFCP may result in hepatic damage. However, the 
extent of damage is highly dependent on the dose and 
duration of administration. Hence, use of doses within 
therapeutic limits is instructive especially in the traditional 
and indiscriminate use of plant decoctions and extracts.
Histopathological examination of liver, kidney and 
prostrate of animals orally administered MFCP for 30 
days showed severe diffuse vacuolar degeneration of 
hepatocytes in livers of animals that received the highest 
dose (200 mg/kg). Similarly, protein casts were also 
abundant in kidneys of animals that received the highest 
dose of 200 mg/kg, which suggests that the kidney tubules 
may be leaky to proteins, while no visible lesions were 
observed in kidneys of animals that received doses 25, 50, 
100 mg/kg MFCP. Furthermore, distortion of the entire 
prostate gland as well as necrotic debris was observed in 
the prostates of animals that received the highest dose of 
200 mg/kg. Taken together, these observations suggest 
that MFCP could be toxic at higher doses, hence should 
be taken with caution.
Furthermore, activation of initiator caspase-9 and 
executioner caspase-3 was observed at 100 mg/kg and 200 
mg/kg dosage groups. However, there was no significant 
activation of caspase-3 and 9 at lower dosage groups (25 
and 50 mg/kg). This is in consonance with our previous 
data that there was no induction of pore opening at 
these doses. The mPT is therefore a decisive event which 
defines the thin line between cell survival and death with 
mitochondrial membranes serving as a battlefield on 
which various signals combat to decide the fate of the cell 
(19).
Conclusion
In summary, these results demonstrate that MFCP-
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induced apoptosis was mediated by induction of the 
opening of mPT pore which resulted in the activation of 
caspases-9 and 3. This effect will be useful for evaluation 
of the potency of MFCP as an anti-tumor agent in prostate 
cancer cell lines. However, safety of the plant should be 
considered when administering for therapeutic purposes.
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